MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Euronext Paris 17:30:01 24/05/2024 BST | ||
| 3.55 EUR | -2.20% |
|
| Current month | +16.47% | ||
| 1 month | +22.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 3.5 | -3.58% |
| 23/05/24 | 3.63 | +7.08% |
| 22/05/24 | 3.39 | -0.73% |
| 21/05/24 | 3.415 | +10.52% |
| 17/05/24 | 3.09 | -5.50% |
Real-time Euronext Paris
Last update May 24, 2024 at 05:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| XQ8NB | |
| ISIN | FRBNPP06JU76 |
| Date issued | 05/03/2024 |
| Strike | 675.4 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.63 € |
|---|---|
| Lowest since issue | 2.165 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
928.8
DKK
Average target price
909.2
DKK
Spread / Average Target
-2.11%
- Stock Market
- Certificates
- XQ8NB Certificat
